Ebola : two vaccines to be effective for at least a year

Vaccination during the trial, PREVAIL (PREVAIL)

Published the 12.10.2017 at 15: 45

A A

Keywords :

ebolaessai cliniquevaccinAfrique of the West

Quickly made, well done. The vaccine against Ebola, developed by the emergency at the time of the epidemic in West Africa, exhibit a good safety profile. According to a large study conducted in Liberia in 2014, few side effects have been reported in the year following the injection. Good news reported in the New England Journal of Medicine.

The clinical trial in question, PREVAIL, has been conducted in the heart of the Ebola epidemic. 1 500 adults were recruited by teams americo-liberian. They were separated into three groups : those who received a placebo, and those who have tested two candidate vaccines (cAd3-EBOZ and rVSV-ZEBOV).

A sustainable efficiency

A certain time is required before the volunteers to develop a response to the vaccine, which is characterized by the production of antibodies. It appears that, at the end of a month. Has this study period, 71 % and 84 % of the participants exposed to the vaccine candidates exhibit a satisfactory response. This phenomenon is marginal in the group treated with placebo.

A year after the experience, the benefits of the gesture are still present. Two-thirds of participants who received cAd3-EBOZ still have antibodies. In the group that has been exposed to rVSV-ZEBOV, the same observation applies to the eight volunteers on ten.

The presence of antibodies among the members of the placebo group is surprising. In fact, at the beginning of the study, 4% of the participants already possessed. As defined by the researchers, this is the sign that Ebola virus took place, but that it did not cause symptoms.